bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table. S1 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Details of primers used for optimization, quantitative gene expression, and PCR analysis in CWR22 and LuCaP35 tumor xenografts and cell lines.
Supplementary data file from PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Authors: Kluger Harriet M. , Zito Christopher R. , Turcu Gabriela , Baine Marina K. , Zhang Hongyi , Adeniran Adebowale , Sznol Mario , Rimm David L. , Kluger Yuval , Chen Lieping , Cohen Justine V. , Jilaveanu Lucia B.
Published: April 2023

Supplementary tables and supplementary figure legends
Supplementary Figure 3. from PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Authors: Kluger Harriet M. , Zito Christopher R. , Turcu Gabriela , Baine Marina K. , Zhang Hongyi , Adeniran Adebowale , Sznol Mario , Rimm David L. , Kluger Yuval , Chen Lieping , Cohen Justine V. , Jilaveanu Lucia B.
Published: April 2023

Pearson correlation of PD-L1 expression measured by 5H1 or E1L3N clones.
Supplementary Figure 2 from PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Authors: Kluger Harriet M. , Zito Christopher R. , Turcu Gabriela , Baine Marina K. , Zhang Hongyi , Adeniran Adebowale , Sznol Mario , Rimm David L. , Kluger Yuval , Chen Lieping , Cohen Justine V. , Jilaveanu Lucia B.
Published: April 2023

Correlation of PD-L1 expression between maximum and mean immunofluorescence scores measured within the tumor compartment or stroma.
Supplementary Tables from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

Supplementary Tables
Supplemental Table 2 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Authors: Assadipour Yasmine , Zacharakis Nikolaos , Crystal Jessica S. , Prickett Todd D. , Gartner Jared J. , Somerville Robert P.T. , Xu Hui , Black Mary A. , Jia Li , Chinnasamy Harshini , Kriley Isaac , Lu Lily , Wunderlich John R. , Zheng Zhili , Lu Yong-Chen , Robbins Paul F. , Rosenberg Steven A. , Goff Stephanie L. , Feldman Steven A.
Published: April 2023

Phenotypic characterization of TIL.
Supplementary Figure S1 from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

Analysis of gene expression and RT-qPCR data in strata of class of response: hyperprogressors (HP), progressors (P), stable disease (SD) and reponders (R).
Supplementary Data from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

This files describes supplementary materials and methods
Table S3 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Authors: George Daniel J. , Martini Jean-Francois , Staehler Michael , Motzer Robert J. , Magheli Ahmed , Donskov Frede , Escudier Bernard , Li Sherry , Casey Michelle , Valota Olga , Laguerre Brigitte , Pantuck Allan J. , Pandha Hardev S. , Patel Anup , Lechuga Maria , Ravaud Alain
Published: April 2023

Association between DFS and genotype subgroups within each treatment group or the combined sunitinib and placebo groups
Table S2 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Authors: George Daniel J. , Martini Jean-Francois , Staehler Michael , Motzer Robert J. , Magheli Ahmed , Donskov Frede , Escudier Bernard , Li Sherry , Casey Michelle , Valota Olga , Laguerre Brigitte , Pantuck Allan J. , Pandha Hardev S. , Patel Anup , Lechuga Maria , Ravaud Alain
Published: April 2023

Genotype frequency
Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Authors: Ni Haiwen , Shirazi Fazal , Baladandayuthapani Veerabhadran , Lin Heather , Kuiatse Isere , Wang Hua , Jones Richard J. , Berkova Zuzana , Hitoshi Yasumichi , Ansell Stephen M. , Treon Steven P. , Thomas Sheeba K. , Lee Hans C. , Wang Zhiqiang , Davis R. Eric , Orlowski Robert Z.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 4 from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Figure 4: Investigation of the p.L1049R mutation identified in a patient with castration-resistant prostate cancer.
Supplementary Table S2: Characteristics of the 133 patients with CTC measurements at both time points from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Detection of CTCs associated with patient and tumor characteristics for both time points in patients with measurements at both time points is listed. There was no significant correlation of {greater than or equal to}1CTC or {greater than or equal to}2CTCs to any of these parameters.
Supplementary Figure 1 legend from Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer
Authors: Saylor Philip J. , Lee Richard J. , Arora Kshitij S. , Deshpande Vikram , Hu Rong , Olivier Kara , Meneely Erika , Rivera Miguel N. , Ting David T. , Wu Chin-Lee , Miyamoto David T.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 1 from Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer
Authors: Saylor Philip J. , Lee Richard J. , Arora Kshitij S. , Deshpande Vikram , Hu Rong , Olivier Kara , Meneely Erika , Rivera Miguel N. , Ting David T. , Wu Chin-Lee , Miyamoto David T.
Published: April 2023

Control cell line validations.
Supplementary Table and Figure Legends from EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Authors: Jorge Susan E. , Lucena-Araujo Antonio R. , Yasuda Hiroyuki , Piotrowska Zofia , Oxnard Geoffrey R. , Rangachari Deepa , Huberman Mark S. , Sequist Lecia V. , Kobayashi Susumu S. , Costa Daniel B.
Published: April 2023

Supplementary Table and Figure Legends
Table S3 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

17βHSD2 staining density in patient specimens.
Supplementary Data Figure 2 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

HSD17B2 knockout in MDA-Pca-2b cells.
Supplemental Information from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

Supplemental Materials and Methods, References, and Figure Legends
Figure S3 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

PAPSS1-silenced H358 cells are more sensitive to cisplatin treatment when starved
Figure S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Authors: Joseph Richard W. , Elassaiss-Schaap Jeroen , Kefford Richard , Hwu Wen-Jen , Wolchok Jedd D. , Joshua Anthony M. , Ribas Antoni , Hodi F. Stephen , Hamid Omid , Robert Caroline , Daud Adil , Dronca Roxana , Hersey Peter , Weber Jeffrey S. , Patnaik Amita , de Alwis Dinesh P. , Perrone Andrea , Zhang Jin , Kang S. Peter , Ebbinghaus Scot , Anderson Keaven M. , Gangadhar Tara C.
Published: April 2023

Supplemental Figure
Supplementary Table S2 and S3 from Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Authors: Xu Qingyu , Li Yan , Lv Na , Jing Yu , Xu Yihan , Li Yuyan , Li Wenjun , Yao Zilong , Chen Xiaosu , Huang Sai , Wang Lili , Li Yonghui , Yu Li
Published: April 2023

Supplementary Table S1. General statistics of studies included in the meta-analysis; Supplementary Table S2. Egger's and Begg's tests for publication bias. Supplementary Table S3. Pooled HRs or RRs calculated by random effect model and fixed effect model.
Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Authors: Mueller Karen Thudium , Waldron Edward , Grupp Stephan A. , Levine John E. , Laetsch Theodore W. , Pulsipher Michael A. , Boyer Michael W. , August Keith J. , Hamilton Jason , Awasthi Rakesh , Stein Andrew M. , Sickert Denise , Chakraborty Abhijit , Levine Bruce L. , June Carl H. , Tomassian Lori , Shah Sweta S. , Leung Mimi , Taran Tetiana , Wood Patricia A. , Maude Shannon L.
Published: April 2023

Supplementary Data
Supplementary Table S6 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S6. Genes in the SROs of 1q and 19 deletions
Supplementary Data from Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Authors: Le Xiuning , Puri Sonam , Negrao Marcelo V. , Nilsson Monique B. , Robichaux Jacqulyne , Boyle Theresa , Hicks J. Kevin , Lovinger Katherine L. , Roarty Emily , Rinsurongkawong Waree , Tang Ming , Sun Huiying , Elamin Yasir , Lacerda Lara C. , Lewis Jeff , Roth Jack A. , Swisher Stephen G. , Lee J. Jack , William William N. , Glisson Bonnie S. , Zhang Jianjun , Papadimitrakopoulou Vassiliki A. , Gray Jhanelle E. , Heymach John V.
Published: April 2023

Supplementary material methods figures and tables
Supplementary Table S2 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S2. Samples' information and clinical information of stage 4 neuroblastoma patients included in the cohort
Supplemental Table S2. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers
Authors: Kawakami Eiryo , Tabata Junya , Yanaihara Nozomu , Ishikawa Tetsuo , Koseki Keita , Iida Yasushi , Saito Misato , Komazaki Hiromi , Shapiro Jason S. , Goto Chihiro , Akiyama Yuka , Saito Ryosuke , Saito Motoaki , Takano Hirokuni , Yamada Kyosuke , Okamoto Aikou
Published: April 2023

Diagnostic accuracy of clinicopathological factors using Machine Learning Algorithms
Supplemental Table S1. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers
Authors: Kawakami Eiryo , Tabata Junya , Yanaihara Nozomu , Ishikawa Tetsuo , Koseki Keita , Iida Yasushi , Saito Misato , Komazaki Hiromi , Shapiro Jason S. , Goto Chihiro , Akiyama Yuka , Saito Ryosuke , Saito Motoaki , Takano Hirokuni , Yamada Kyosuke , Okamoto Aikou
Published: April 2023

Pretreatment peripheral blood tests of 334 patients with epithelial ovarian cancer and 101 patients with benign ovarian tumor
Supplemental Figure S1. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers
Authors: Kawakami Eiryo , Tabata Junya , Yanaihara Nozomu , Ishikawa Tetsuo , Koseki Keita , Iida Yasushi , Saito Misato , Komazaki Hiromi , Shapiro Jason S. , Goto Chihiro , Akiyama Yuka , Saito Ryosuke , Saito Motoaki , Takano Hirokuni , Yamada Kyosuke , Okamoto Aikou
Published: April 2023

Supplemental Figure S1. Explanation and evaluation of the random forest (RF) classifier. (A) Schematic illustration of the classification of samples by the RF. (B, C) Representative classification trees from the discrimination between malignant and benign tumors. These trees are only representations out of 4,000 trees constructed in the RF classifier. The final class is determined as a result of voting by all 4,000 trees. (D, E) The highest accuracy of prediction (D) and the AUC (E) using different numbers of samples in RF classification between malignant and benign tumors. The mean accuracy and AUC with these 95% confidence intervals were presented for 10 independent sets of randomly selected data of 20%, 40%, 60%, and 80% of patients from the training and test cohorts.
Supplementary methods from Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Authors: Aftimos Philippe , Rolfo Christian , Rottey Sylvie , Offner Fritz , Bron Dominique , Maerevoet Marie , Soria Jean-Charles , Moshir Mahan , Dreier Torsten , Van Rompaey Luc , Michot Jean-Marie , Silence Karen , Hultberg Anna , Gandini Domenica , de Haard Hans , Ribrag Vincent , Peeters Marc , Thibault Alain , Leupin Nicolas , Awada Ahmad
Published: April 2023

More details about inclusion and exclusion criteria
Figure S8 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

The combination of AZD9291 with PF02341066 exerts limited effects on suppressing the growth of PC-9-derived AZD9291-resistant cell lines
Supplementary data from Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma
Authors: Xu Jing , Liang Jing , Meng Ya-Ming , Yan Jing , Yu Xing-Juan , Liu Chao-Qun , Xu Li , Zhuang Shi-Mei , Zheng Limin
Published: April 2023

Supplementary materials + tables + figures
Supplementary Figure 2: VAC14 Knockdown and neuronal cell sensitivity to docetaxel or paclitaxel for additional morphological phenotypes from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

Peripheral neuronal cells (Peri.4U) treated with docetaxel were found to have a significant decrease in sensitivity for A) mean process lengths but not for B) mean outgrowth intensity or C) relative straightness as measured after 24 hours post-drug treatment. For paclitaxel treatment at the same time point, the cells were also found to have significantly decreased sensitivity for D) relative mean process length and E) mean outgrowth intensity but not for F) relative straightness. Neurite parameters measured with MetaXPress® software were averaged from 3 independent experiments. Error bars represent the standard error of the mean from three independent transfection experiments. NTC = non-targeting control, UT= untransfected control.
Supplemental Materials and Methods from Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer
Authors: Hamilton Duane H. , Griner Lesley Mathews , Keller Jonathan M. , Hu Xin , Southall Noel , Marugan Juan , David Justin M. , Ferrer Marc , Palena Claudia
Published: April 2023

Detailed description of the high-throughput screen assay
Supplemental Table 1 from Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors
Authors: London Cheryl A. , Acquaviva Jaime , Smith Donald L. , Sequeira Manuel , Ogawa Luisa Shin , Gardner Heather L. , Bernabe Louis Feo , Bear Misty D. , Bechtel Sandra A. , Proia David A.
Published: April 2023

Supplementary Table 1: Adverse Events
Supplementary Figure S3 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S3: Evolution of mutational signatures in treatment-naÃ¯ve patients with de novo synchronous metastatic breast cancer. (A) Heatmap represents the similarity of the observed mutational signatures (blue, see color key) to those previously observed in human cancers (15, 36), separately for the trunk mutations (yellow), the mutations specific to the primary tumor (green) and the mutations specific to the metastatic lesion (pink). (B) Barplots illustrate the mutational signatures of the mutations specific to the primary tumor and the metastatic lesion of Cases 2, 4, 7 and 9. In each panel, the colored barplot illustrates each mutational signature according to the 96 substitution classification defined by the substitution classes (C>A, C>G, C>T, T>A, T>C and T>G bins) and the 5' and 3' sequence context, normalized using the observed trinucleotide frequency in the human exome to that in the human genome. The bars are ordered first by mutation class (C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/A>G, T>G/A >C), then by the 5' flanking base (A, C, G, T) and then by the 3' flanking base (A, C, G, T). *: >20%.
Supplementary Figure S5 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S5. A) Survival analysis of the upregulated (11/27) gene signature in high grade BLCA from the Kim, Lindgren, Sjodahl, and TCGA coherts. B) Survival analysis of the upregulated (11/27) gene signature in low grade BLCA from the Kim, Lindgren, and Sjodahl coherts. Upregulated genes associated with poor survival in the TCGA high-grade (log-rank p<0.0041), the Lindgren high grade cohort (log-rank p<0.0298), and in the Sjodahl low-grade cohort (log-rank p<0.0418). (LG=low-grade, HG= high-grade).
Table S4 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Summary of currently available data looking at biomarkers during antiantiogenic therapy
Figure S3 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Kaplan-Meier analysis of progression-free survival (PFS) and overall survival (OS) according to relative changes in biomarkers during cycle 1 (A-B) and cycle 2 (C). HR, hazard ratio; CI, confidence interval.
Supplemental Tables 1 and 2, and Supplemental Figure Legends from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Supplemental Tables 1 and 2, and Supplemental Figure Legends
Figure S2 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Figure S2 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Supplementary Figures S1, S2, S3 from Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model
Authors: Niknam Sharareh , Barsoumian Hampartsoum B. , Schoenhals Jonathan E. , Jackson Heather L. , Yanamandra Niranjan , Caetano Mauricio S. , Li Ailin , Younes Ahmed I. , Cadena Alexandra , Cushman Taylor R. , Chang Joe Y. , Nguyen Quynh N. , Gomez Daniel R. , Diab Adi , Heymach John V. , Hwu Patrick , Cortez Maria Angelica , Welsh James W.
Published: April 2023

Supplementary Figure S1. XRT (12 Gyx 2) with α-OX40 treatment effect on (A) tumor growth and (B) lung metastases in induction and adjuvant settings. (C) A representative picture depicting the decrease in lung tumor nodules with the combination therapy after staining with Bouin's fixative solution. /// Supplementary Figure S2. Effect of radiation (XRT) on immune-cell profiles in splenocytes (Spl) and draining lymph nodes (dLN). Representative flow cytometry gating of (CD4+OX40+) lymphocytes isolated from (A) spleen and (B) tumor draining lymph node of mice at 48 h after XRT (12 Gyx 3) or no XRT to anti-PD1 resistant tumors. /// Supplementary Figure S3. XRT upregulates OX40+ CD8 T-cells and enhances OX40L expression in neutrophils. (A) In anti-PD1-resistant 344SQ tumor model, XRT given as three 12-Gy fractions (total dose 36 Gy) increased the percentages of CD8+ T-cells expressing OX40 in the splenocytes 48 h after last dose of radiation. (B) Percent neutrophils expressing OX40L isolated from splenocytes 48 h after XRT. Cells are first gated on leukocytes then Gr1hi CD11b+ cells then on OX40L+ population. *P {less than or equal to} 0.05 is considered significant.
Supplementary Information from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Supplementary Information
supplemental data from Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis
Authors: Nyman Patrick E. , Buehler Darya , Lambert Paul F.
Published: April 2023

supplemental figure 1: Analysis of MCM7 and HES1 expression in normal and cancerous epithelia for the HPV-negative chort. Supplemental Fig 2: Cutaneous Squamous Cell Carcinoma present in the skin surrounding the mouth of DNMAML1-expressing mice.
Table S2 from Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis
Authors: Noda Masaru , Okayama Hirokazu , Tachibana Kazunoshin , Sakamoto Wataru , Saito Katsuharu , Thar Min Aung Kyi , Ashizawa Mai , Nakajima Takahiro , Aoto Keita , Momma Tomoyuki , Katakura Kyoko , Ohki Shinji , Kono Koji
Published: April 2023

Table S2
Table S1 from Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis
Authors: Noda Masaru , Okayama Hirokazu , Tachibana Kazunoshin , Sakamoto Wataru , Saito Katsuharu , Thar Min Aung Kyi , Ashizawa Mai , Nakajima Takahiro , Aoto Keita , Momma Tomoyuki , Katakura Kyoko , Ohki Shinji , Kono Koji
Published: April 2023

Supplementary Table S1. List of NCBI-GEO datasets used in this study.
Figure S1 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Authors: Sharma Priyanka , López-Tarruella Sara , García-Saenz José Angel , Khan Qamar J. , Gómez Henry L. , Prat Aleix , Moreno Fernando , Jerez-Gilarranz Yolanda , Barnadas Agustí , Picornell Antoni C. , Monte-Millán María del , González-Rivera Milagros , Massarrah Tatiana , Pelaez-Lorenzo Beatriz , Palomero María Isabel , González del Val Ricardo , Cortés Javier , Fuentes-Rivera Hugo , Morales Denisse Bretel , Márquez-Rodas Iván , Perou Charles M. , Lehn Carolyn , Wang Yen Y. , Klemp Jennifer R. , Mammen Joshua V. , Wagner Jamie L. , Amin Amanda L. , O’Dea Anne P. , Heldstab Jaimie , Jensen Roy A. , Kimler Bruce F. , Godwin Andrew K. , Martín Miguel
Published: April 2023

Pathological response to carboplatin plus docetaxel by germline BRCA status
Table S2 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Multivariate Cox Proportional Hazards Analysis of DS, RT and Study Site by Risk Groups
Table S1 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Immune-related gene list.
Figure S3 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vivo PD-L2 expression in APCs from MC-38 tumor.
Supplementary Table S3 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S3 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Supplementary Data from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Data from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Figures S1-S14, Tables S1-S2 from Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment
Authors: Riegler Johannes , Labyed Yassin , Rosenzweig Stephen , Javinal Vincent , Castiglioni Alessandra , Dominguez Claudia X. , Long Jason E. , Li Qingling , Sandoval Wendy , Junttila Melissa R. , Turley Shannon J. , Schartner Jill , Carano Richard A.D.
Published: April 2023

Supplementary methods, supplementary figures and tables
Supplementary Figure 6 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

MAPK reliance in LAPC4
Suppl. Table S1 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

Antibodies, compounds, oligonucleotides, and other reagents used in the study
Supplementary Table 1 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Mahalingam Devalingam , Wang Judy S. , Hamilton Erika P. , Sarantopoulos John , Nemunaitis John , Weems Garry , Carter Laura , Hu Xiao , Schreeder Marshall , Wilkins H. Jeffrey
Published: April 2023

Pharmacokinetic results at Day 29, by cohort (median [range])
Figure A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Authors: Chahoud Jad , Sui Dawen , Erwin William D. , Gulbis Alison M. , Korbling Martin , Zhang Mingzhi , Ahmed Sairah , Alatrash Gheath , Anderlini Paolo , Ciurea Stefan O. , Oran Betul , Fayad Luis E. , Bassett Roland L. , Jabbour Elias J. , Medeiros L. Jeffrey , Macapinlac Homer A. , Young Ken H. , Khouri Issa F.
Published: April 2023

Progression-free survival curves for groups A, B, C, and D.
Supplementary Figure 2 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Mahalingam Devalingam , Wang Judy S. , Hamilton Erika P. , Sarantopoulos John , Nemunaitis John , Weems Garry , Carter Laura , Hu Xiao , Schreeder Marshall , Wilkins H. Jeffrey
Published: April 2023

Post-treatment changes in IL-17A and pharmacokinetic profiles for Cohort 4a (600 mg QD) and Cohort 4b (300 mg BID). D, day; PD, pharmacodynamics; PK, pharmacokinetics.
Supplementary Figure 1 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Mahalingam Devalingam , Wang Judy S. , Hamilton Erika P. , Sarantopoulos John , Nemunaitis John , Weems Garry , Carter Laura , Hu Xiao , Schreeder Marshall , Wilkins H. Jeffrey
Published: April 2023

LYC-55716 toxicology thermometer plot indicating a pharmacologically active exposure of 18.6μg·h/mL, based on the upregulation of target genes in mouse thymus
Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Authors: Beshiri Michael L. , Tice Caitlin M. , Tran Crystal , Nguyen Holly M. , Sowalsky Adam G. , Agarwal Supreet , Jansson Keith H. , Yang Qi , McGowen Kerry M. , Yin JuanJuan , Alilin Aian Neil , Karzai Fatima H. , Dahut William L. , Corey Eva , Kelly Kathleen
Published: April 2023

Supplementary Tables
Figure S4 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

Immunohistochemical staining of GSDME in a lung cancer tissue microarray and a patient cohort with KRAS-mutant, EGFR-altered or ALK-rearranged lung adenocarcinoma.
Supplementary Figures from Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity
Authors: Peters Tara L. , Tillotson Joseph , Yeomans Alison M. , Wilmore Sarah , Lemm Elizabeth , Jiménez-Romero Carlos , Amador Luis A. , Li Lingxiao , Amin Amit D. , Pongtornpipat Praechompoo , Zerio Christopher J. , Ambrose Andrew J. , Paine-Murrieta Gillian , Greninger Patricia , Vega Francisco , Benes Cyril H. , Packham Graham , Rodríguez Abimael D. , Chapman Eli , Schatz Jonathan H.
Published: April 2023

Figure S1. Elatol was submitted to a 96-member kinome screen to evaluate specificity. Figure S2. A) Michaelis-Menten curves of eIF4A1 wild type (blue), K82R (red), and K238E (green). Michaelis- Menten constants for eIF4A1 wild type and mutants in table on the left. B) Chemical structures of elatol and three other known eIF4A inhibitors. Figure S3. A) Cell viability following 72h carbopaltin treatment measured using Cell Titer Glo. Figure S4. A) Western blot showing protein expression of translationally regulated genes in RIVA cells treated with DMSO Figure S5. A) Western blot analysis of MDA-MB-468 breast cancer cells transfected with 50nM ATF4 siRNA or a non-targeting control (NT). Figure S6. A) Mouse weights measured twice weekly during first maximum tolerated dose study.
Supplementary Methods from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Authors: Prete Alessandro , Lo Agnes S. , Sadow Peter M. , Bhasin Swati S. , Antonello Zeus A. , Vodopivec Danica M. , Ullas Soumya , Sims Jennifer N. , Clohessy John , Dvorak Ann M. , Sciuto Tracey , Bhasin Manoj , Murphy-Ullrich Joanne E. , Lawler Jack , Karumanchi S. Ananth , Nucera Carmelo
Published: April 2023

Supplementary Methods
Supplementary Figures 1-12 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Authors: Prete Alessandro , Lo Agnes S. , Sadow Peter M. , Bhasin Swati S. , Antonello Zeus A. , Vodopivec Danica M. , Ullas Soumya , Sims Jennifer N. , Clohessy John , Dvorak Ann M. , Sciuto Tracey , Bhasin Manoj , Murphy-Ullrich Joanne E. , Lawler Jack , Karumanchi S. Ananth , Nucera Carmelo
Published: April 2023

Suppl. Figure 1 Drug dose-effect analysis in BRAFWT/V600E-KTC1 cells Suppl.Figure 2 Dose-effect analysis of vemurafenib and sorafenib on pericyte viability. Suppl. Figure 3 BRAFWT/WT-TPC1 cells viability assay. Suppl. Figure 4 ELISA analysis of cytokines secretion in pericytes, and PTC cells harboring the heterozygous BRAFWT/V600E mutation or with BRAFWT/WT. Suppl. Figure 5 Effects of pericyte secretome in BRAFWT/WT-TPC1 cells. Suppl. Figure 6 Analysis of secreted TSP-1 levels in PTC cells harboring the heterozygous BRAFWT/V600E mutation or with BRAFWT/WT treated with shTSP-1 or shGFP (control) pericyte secretome. Suppl. Figure 7 Effects of shTSP-1 pericyte secretome in BRAFWT/WT-TPC1 cells. Suppl. Figure 8 Viability assay in the presence of SRI31277 in PTC cells and pericytes. Suppl. Figure 9 Effects of the small molecule SRI31277 in PTC cells with BRAFWT/WT. Suppl. Figure 10 THBS1 (TSP-1) mRNA expression levels in PTC samples harboring both BRAFWT/V600E and hTERT mutations compared to BRAFWT/V600E-PTC samples. Suppl. Figure 11 THBS1 (TSP-1) mRNA expression levels in PTC samples harboring both BRAFWT/V600E and hTERT mutations compared to BRAFWT/WT-PTC samples. Suppl. Figure 12 THBS1 (TSP-1) gene regulatory networks pathways in PTC harboring BRAFWT/V600E and hTERT mutations compared to BRAFWT/WT-PTC clinical samples.
Figure S7-S8 from Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Authors: Chen Xian , Low Kwang-Huei , Alexander Angela , Jiang Yufeng , Karakas Cansu , Hess Kenneth R. , Carey Jason P.W. , Bui Tuyen N. , Vijayaraghavan Smruthi , Evans Kurt W. , Yi Min , Ellis D. Christian , Cheung Kwok-Leung , Ellis Ian O. , Fu Siqing , Meric-Bernstam Funda , Hunt Kelly K. , Keyomarsi Khandan
Published: April 2023

supplementary figure 7-8
Supplementary Table S2 from Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Authors: Kim Tae Won , Peeters Marc , Thomas Anne , Gibbs Peter , Hool Kristina , Zhang Jianqi , Ang Agnes Lee , Bach Bruce Allen , Price Timothy
Published: April 2023

Distribution of Plasma RAS, BRAF and EGFR Exon Status at Baseline
Supplemental tables and legends from A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
Authors: Méndez Eduardo , Rodriguez Cristina P. , Kao Michael C. , Raju Sharat , Diab Ahmed , Harbison R. Alex , Konnick Eric Q. , Mugundu Ganesh M. , Santana-Davila Rafael , Martins Renato , Futran Neal D. , Chow Laura Q.M.
Published: April 2023

supplemental tables and legends (no revisions, re-uploaded)
Supplementary Table 1 from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Authors: Lowery Maeve A. , Ptashkin Ryan , Jordan Emmet , Berger Michael F. , Zehir Ahmet , Capanu Marinela , Kemeny Nancy E. , O'Reilly Eileen M. , El-Dika Imane , Jarnagin William R. , Harding James J. , D'Angelica Michael I. , Cercek Andrea , Hechtman Jaclyn F. , Solit David B. , Schultz Nikolaus , Hyman David M. , Klimstra David S. , Saltz Leonard B. , Abou-Alfa Ghassan K.
Published: April 2023

Molecular predictors of progression free survival in patients treated with cytotoxic chemotherapy
Supplementary Figure S5 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Authors: Lee Jong Woo , Parameswaran Janaki , Sandoval-Schaefer Teresa , Eoh Kyung Jin , Yang Dong-hua , Zhu Fang , Mehra Ranee , Sharma Roshan , Gaffney Stephen G. , Perry Elizabeth B. , Townsend Jeffrey P. , Serebriiskii Ilya G. , Golemis Erica A. , Issaeva Natalia , Yarbrough Wendell G. , Koo Ja Seok , Burtness Barbara
Published: April 2023

Supplementary Figure S5 related to Figure 5H. (A) Heat map QIF of pCDK1 expression intensity in FaDu xenograft mice treated with (a) vehicle, (b) alisertib, (c) adavosertib or (d) alisertib+adavosertib. Scores range from very low (purple) to high (yellow). Black squares represent FOVs in which QIF scores were not calculated due to presence of artifacts, lack of tumor, etc. (B) Graph depicts Mean {plus minus} SD of QIF scores of pCDK1 in nuclei in tumor. The expression of pCDK1 is significantly reduced in adavosertib and alisertib+adavosertib treated FaDu-xenografted mice. Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparisons test (****: P < 0.0001; n.s.: not significant).
Supplementary Figure S4 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Authors: Lee Jong Woo , Parameswaran Janaki , Sandoval-Schaefer Teresa , Eoh Kyung Jin , Yang Dong-hua , Zhu Fang , Mehra Ranee , Sharma Roshan , Gaffney Stephen G. , Perry Elizabeth B. , Townsend Jeffrey P. , Serebriiskii Ilya G. , Golemis Erica A. , Issaeva Natalia , Yarbrough Wendell G. , Koo Ja Seok , Burtness Barbara
Published: April 2023

Supplementary Figure S4 related to Figure 5D-F. (A) Individual tumor volume changes in Detroit 562-xenografted mice treated with vehicle, adavosertib (30 mg/kg, daily, p.o.), alisertib (30 mg/kg, daily, p.o.), or the combinations of alisertib with adavosertib. Tumor volume changes of all mice belonged to this study was shown in bottom panel (n = 6 per group). Significant differences between the combination and single drug alone are shown. (B) Body weight (g) of mice was monitored every other day. Graphs depict Mean {plus minus} SEM.
Figure S3 from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma
Authors: Li Hong , Li Junjie , Chen Lei , Qi Songtao , Yu Shishi , Weng Zhijian , Hu Ziyou , Zhou Qiang , Xin Zong , Shi Linyong , Ma Liyi , Huang Annie , Lu Yuntao
Published: April 2023

HERC3 overexpression is observed in the pseudo-palisades cells surrounding tumor necrosis and in tumor-adjacent tissue
Supplementary Data from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Authors: Lee Jong Woo , Parameswaran Janaki , Sandoval-Schaefer Teresa , Eoh Kyung Jin , Yang Dong-hua , Zhu Fang , Mehra Ranee , Sharma Roshan , Gaffney Stephen G. , Perry Elizabeth B. , Townsend Jeffrey P. , Serebriiskii Ilya G. , Golemis Erica A. , Issaeva Natalia , Yarbrough Wendell G. , Koo Ja Seok , Burtness Barbara
Published: April 2023

Supplementary figure legends
Figure S1 from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma
Authors: Li Hong , Li Junjie , Chen Lei , Qi Songtao , Yu Shishi , Weng Zhijian , Hu Ziyou , Zhou Qiang , Xin Zong , Shi Linyong , Ma Liyi , Huang Annie , Lu Yuntao
Published: April 2023

Autophagy inducer rapamycin increases cellular migration and invasion and mediates EMT in GBM cells
Supplementary Data from Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Davids Matthew S. , Hallek Michael , Wierda William , Roberts Andrew W. , Stilgenbauer Stephan , Jones Jeffrey A. , Gerecitano John F. , Kim Su Young , Potluri Jalaja , Busman Todd , Best Andrea , Verdugo Maria E. , Cerri Elisa , Desai Monali , Hillmen Peter , Seymour John F.
Published: April 2023

Supplementary Data
Figure S4 from Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Authors: Toker Aras , Nguyen Linh T. , Stone Simone C. , Yang S.Y. Cindy , Katz Sarah Rachel , Shaw Patricia A. , Clarke Blaise A. , Ghazarian Danny , Al-Habeeb Ayman , Easson Alexandra , Leong Wey L. , McCready David R. , Reedijk Michael , Guidos Cynthia J. , Pugh Trevor J. , Bernardini Marcus Q. , Ohashi Pamela S.
Published: April 2023

Gating strategy and bivariate analysis of mass cytometry data
Figure S2 from Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Authors: Toker Aras , Nguyen Linh T. , Stone Simone C. , Yang S.Y. Cindy , Katz Sarah Rachel , Shaw Patricia A. , Clarke Blaise A. , Ghazarian Danny , Al-Habeeb Ayman , Easson Alexandra , Leong Wey L. , McCready David R. , Reedijk Michael , Guidos Cynthia J. , Pugh Trevor J. , Bernardini Marcus Q. , Ohashi Pamela S.
Published: April 2023

Global analyses of RNA-Seq data and expression of canonical Treg cell genes